|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Astellas Pharma Inc |
|---|---|
| Information provided by: | Astellas Pharma Inc |
| ClinicalTrials.gov Identifier: | NCT00371774 |
Purpose
Purpose:
To develop a real time national clinical database to support and share best practices,
Each patient visit will include the following observational endpoints:
| Study Type: | Observational |
| Study Design: | Case-Only, Prospective |
| Official Title: | Amevive Wisdom Acquired From Real-Time Evidence (A.W.A.R.E™) Program |
| Enrollment: | 426 |
| Study Start Date: | June 2005 |
| Study Completion Date: | May 2008 |
| Primary Completion Date: | May 2008 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
1
Dermatologic patients in Canada for which Amevive is clinically indicated
|
Eligibility| Ages Eligible for Study: | 16 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Dermatologic patients in Canada
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Canada | |
| Quebec, Canada, G1J 1X7 | |
| Canada, Alberta | |
| Calgary, Alberta, Canada, T3A 2N1 | |
| Calgary, Alberta, Canada, T2S 3B3 | |
| Edmonton, Alberta, Canada, T5J 3S9 | |
| Edmonton, Alberta, Canada, T5K 1X3 | |
| Canada, British Columbia | |
| Surrey, British Columbia, Canada, V3R6A7 | |
| Victoria, British Columbia, Canada, V8V 4X3 | |
| Victoria, British Columbia, Canada, V8V 3P9 | |
| Vancouver, British Columbia, Canada, V5Z 4E8 | |
| Vancouver, British Columbia, Canada, V5Z 3Y1 | |
| Canada, Manitoba | |
| Winnipeg, Manitoba, Canada, R3C 1R4 | |
| Canada, New Brunswick | |
| Moncton, New Brunswick, Canada, E1C 8X3 | |
| Saint John, New Brunswick, Canada, E2M 3W5 | |
| Canada, Newfoundland and Labrador | |
| St. John's, Newfoundland and Labrador, Canada, A1B 4S8 | |
| St. John's, Newfoundland and Labrador, Canada, A1B 3E1 | |
| St John's, Newfoundland and Labrador, Canada, A1B 3A1 | |
| Canada, Nova Scotia | |
| Halifax, Nova Scotia, Canada, B3H 124 | |
| Canada, Ontario | |
| Toronto, Ontario, Canada, M5S 1B6 | |
| London, Ontario, Canada, N6H 1S9 | |
| Concord, Ontario, Canada, L4K 5V2 | |
| Markham, Ontario, Canada, L3P 1A8 | |
| Waterloo, Ontario, Canada, N2J 1C4 | |
| Barrie, Ontario, Canada, L7M 6L7 | |
| Windsor, Ontario, Canada, N8W 5L7 | |
| Hamilton, Ontario, Canada, L8N 3H7 | |
| London, Ontario, Canada, N6A 3H7 | |
| Oakville, Ontario, Canada, L6K 1E1 | |
| Canada, Quebec | |
| Sainte-Foy, Quebec, Canada, G1V 4X7 | |
| Montreal, Quebec, Canada, H3G 1A1 | |
| Montreal, Quebec, Canada, H2K 4L5 | |
| Study Director: | Use Central Contact | Astellas Pharma Canada, Inc. |
More Information
| Responsible Party: | Astellas Pharma US, Inc. ( Sr Manager Clinical Trials Registry ) |
| Study ID Numbers: | CA-08 |
| Study First Received: | August 31, 2006 |
| Last Updated: | July 14, 2008 |
| ClinicalTrials.gov Identifier: | NCT00371774 History of Changes |
| Health Authority: | Canada: Ethics Review Committee |
|
Psoriasis Plaque Psoriasis Amevive® alefacept |
|
Alefacept Skin Diseases Psoriasis Skin Diseases, Papulosquamous |
|
Alefacept Skin Diseases Psoriasis Therapeutic Uses |
Dermatologic Agents Skin Diseases, Papulosquamous Pharmacologic Actions |
